Kamlesh P. Vyas

2.9k total citations
58 papers, 2.3k citations indexed

About

Kamlesh P. Vyas is a scholar working on Pharmacology, Molecular Biology and Pharmacology. According to data from OpenAlex, Kamlesh P. Vyas has authored 58 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pharmacology, 19 papers in Molecular Biology and 12 papers in Pharmacology. Recurrent topics in Kamlesh P. Vyas's work include Pharmacogenetics and Drug Metabolism (22 papers), Inflammatory mediators and NSAID effects (10 papers) and Eicosanoids and Hypertension Pharmacology (8 papers). Kamlesh P. Vyas is often cited by papers focused on Pharmacogenetics and Drug Metabolism (22 papers), Inflammatory mediators and NSAID effects (10 papers) and Eicosanoids and Hypertension Pharmacology (8 papers). Kamlesh P. Vyas collaborates with scholars based in United States, Japan and India. Kamlesh P. Vyas's co-authors include Lynn M. Gorham, Thomayant Prueksaritanont, Byron H. Arison, Wayne Levin, P H Kari, Jerome Hochman, Haruhiko Yagi, Rita A. Halpin, Prasad H. Kari and Paul E. Thomas and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and The FASEB Journal.

In The Last Decade

Kamlesh P. Vyas

58 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kamlesh P. Vyas United States 26 854 606 494 421 385 58 2.3k
Cuyue Tang United States 25 839 1.0× 631 1.0× 627 1.3× 278 0.7× 357 0.9× 66 2.2k
Cosette J. Serabjit‐Singh United States 24 1.2k 1.4× 883 1.5× 1.3k 2.6× 263 0.6× 201 0.5× 40 3.1k
Donald S. Davies United Kingdom 31 1.3k 1.5× 923 1.5× 709 1.4× 213 0.5× 189 0.5× 92 3.0k
Kevin B. Alton United States 26 501 0.6× 691 1.1× 545 1.1× 272 0.6× 790 2.1× 49 2.8k
D E Duggan United States 31 713 0.8× 1.2k 2.0× 741 1.5× 873 2.1× 425 1.1× 76 3.6k
Jordan L. Holtzman United States 32 1.0k 1.2× 1.1k 1.9× 461 0.9× 239 0.6× 173 0.4× 145 3.5k
Roger J. Price United Kingdom 30 1.3k 1.5× 815 1.3× 558 1.1× 193 0.5× 119 0.3× 95 2.6k
Atsushi Kurihara Japan 29 766 0.9× 686 1.1× 559 1.1× 766 1.8× 650 1.7× 88 3.7k
Lysiane Richert France 33 1.1k 1.2× 810 1.3× 668 1.4× 137 0.3× 524 1.4× 129 3.1k
Charles A. Tyson United States 25 932 1.1× 535 0.9× 929 1.9× 128 0.3× 145 0.4× 56 2.2k

Countries citing papers authored by Kamlesh P. Vyas

Since Specialization
Citations

This map shows the geographic impact of Kamlesh P. Vyas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamlesh P. Vyas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamlesh P. Vyas more than expected).

Fields of papers citing papers by Kamlesh P. Vyas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamlesh P. Vyas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamlesh P. Vyas. The network helps show where Kamlesh P. Vyas may publish in the future.

Co-authorship network of co-authors of Kamlesh P. Vyas

This figure shows the co-authorship network connecting the top 25 collaborators of Kamlesh P. Vyas. A scholar is included among the top collaborators of Kamlesh P. Vyas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kamlesh P. Vyas. Kamlesh P. Vyas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tang, Cuyue, Jerome Hochman, Bennett Ma, Raju Subramanian, & Kamlesh P. Vyas. (2003). Acyl Glucuronidation and Glucosidation of a New and Selective Endothelin ETA Receptor Antagonist in Human Liver Microsomes. Drug Metabolism and Disposition. 31(1). 37–45. 35 indexed citations
2.
Babu, J. Moses, et al.. (2002). Isolation and characterisation of process-related impurities in rofecoxib. Journal of Pharmaceutical and Biomedical Analysis. 29(1-2). 355–360. 12 indexed citations
3.
Goldberg, Michael R., David Sciberras, Marina De Smet, et al.. (2001). Influence of β‐adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5‐HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. British Journal of Clinical Pharmacology. 52(1). 69–76. 37 indexed citations
4.
Kari, Prasad H., et al.. (2000). Metabolism of A Dopamine D4-Selective Antagonist in Rat, Monkey, and Humans: Formation of A Novel Mercapturic Acid Adduct. Drug Metabolism and Disposition. 28(6). 633–642. 9 indexed citations
5.
Rao, Kalapala Venkateswara, Anup Kumar Sadhukhan, Vilwanathan Ravikumar, et al.. (2000). Butyrolactones from Aspergillus terreus.. Chemical and Pharmaceutical Bulletin. 48(4). 559–562. 105 indexed citations
6.
Halpin, Rita A., Laura A. Geer, Douglas C. Dean, et al.. (2000). The Absorption, Distribution, Metabolism and Excretion of Rofecoxib, a Potent and Selective Cyclooxygenase-2 Inhibitor, in Rats and Dogs. Drug Metabolism and Disposition. 28(10). 1244–1254. 64 indexed citations
7.
Goldberg, Michael R., Yih Lee, Kamlesh P. Vyas, et al.. (2000). Rizatriptan, a Novel 5‐HT1B/1D Agonist for Migraine: Single‐ and Multiple‐Dose Tolerability and Pharmacokinetics in Healthy Subjects. The Journal of Clinical Pharmacology. 40(1). 74–83. 9 indexed citations
8.
Lagu, Bharat, George Chiu, Dhanapalan Nagarathnam, et al.. (2000). Synthesis and evaluation of furo[3,4-d]pyrimidinones as selective α1a-adrenergic receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 10(2). 175–178. 39 indexed citations
9.
Vickers, S., Anthony D. Theoharides, Byron H. Arison, et al.. (1999). In Vitro and In Vivo Studies on the Metabolism of Tirofiban. Drug Metabolism and Disposition. 27(11). 1360–1366. 32 indexed citations
10.
Prueksaritanont, Thomayant, Lynn M. Gorham, Bennett Ma, et al.. (1997). In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.. PubMed. 25(10). 1191–9. 244 indexed citations
11.
Prueksaritanont, Thomayant, Lynn M. Gorham, Joan D. Ellis, et al.. (1996). Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.. Drug Metabolism and Disposition. 24(11). 1263–1271. 6 indexed citations
12.
Vickers, S., C A Duncan, P H Kari, et al.. (1993). In vivo and in vitro metabolism studies on a class III antiarrhythmic agent.. Drug Metabolism and Disposition. 21(3). 467–473. 9 indexed citations
13.
Smith, Peter F., R. S. Eydelloth, Scott Grossman, et al.. (1991). HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.. Journal of Pharmacology and Experimental Therapeutics. 257(3). 1225–1235. 129 indexed citations
14.
Kari, Prasad H., et al.. (1991). Biotransformation of lovastatin. Archives of Biochemistry and Biophysics. 290(2). 355–361. 166 indexed citations
15.
Vickers, S., C A Duncan, Kamlesh P. Vyas, et al.. (1990). In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.. Drug Metabolism and Disposition. 18(4). 476–483. 136 indexed citations
16.
Vyas, Kamlesh P., P H Kari, S. Vickers, et al.. (1988). Metabolism of simvastatin s by rat and mouse liver microsomes. The FASEB Journal. 2(5). 4444. 1 indexed citations
17.
Vyas, Kamlesh P., Peter J. van Bladeren, Dhiren R. Thakker, et al.. (1983). Regioselectivity and stereoselectivity in the metabolism of trans-1,2-dihydroxy-1,2-dihydrobenz[a]anthracene by rat liver microsomes.. Molecular Pharmacology. 24(1). 115–123. 16 indexed citations
18.
Vyas, Kamlesh P., Wayne Levin, Haruhiko Yagi, et al.. (1982). Stereoselective metabolism of the (+)- and (-)-enantiomers of trans-1,2-dihydroxy-1,2-dihydrochrysene to bay-region 1,2-diol-3,4-epoxide diastereomers by rat liver enzymes.. Molecular Pharmacology. 22(1). 182–189. 25 indexed citations
19.
Yagi, Haruhiko, Kamlesh P. Vyas, Masao Tada, Dhiren R. Thakker, & Donald M. Jerina. (1982). Synthesis of the enantiomeric bay-region diol epoxides of benz[a]anthracene and chrysene. The Journal of Organic Chemistry. 47(6). 1110–1117. 29 indexed citations
20.
Vyas, Kamlesh P., Dhiren R. Thakker, Wayne Levin, et al.. (1982). Stereoselective metabolism of the optical isomers of trans-1,2-dihydroxy-1,2-dihydrophenanthrene to bay-region diol epoxides by rat liver microsomes. Chemico-Biological Interactions. 38(2). 203–213. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cuyue Tang Breakdown of academic impact, for papers by Cosette J. Serabjit‐Singh Breakdown of academic impact, for papers by Donald S. Davies Breakdown of academic impact, for papers by Kevin B. Alton Breakdown of academic impact, for papers by D E Duggan Breakdown of academic impact, for papers by Jordan L. Holtzman Breakdown of academic impact, for papers by Roger J. Price Breakdown of academic impact, for papers by Atsushi Kurihara Breakdown of academic impact, for papers by Lysiane Richert Breakdown of academic impact, for papers by Charles A. Tyson
Rankless by CCL
2026